Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) 10-Year ROIIC % : -10,614.29% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Lixte Biotechnology Holdings 10-Year ROIIC %?

10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year. Lixte Biotechnology Holdings's 10-Year ROIIC % for the quarter that ended in Dec. 2023 was -10,614.29%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Lixte Biotechnology Holdings's 10-Year ROIIC % or its related term are showing as below:

LIXT's 10-Year ROIIC % is ranked worse than
99.04% of 1352 companies
in the Biotechnology industry
Industry Median: -35.035 vs LIXT: -10614.29

Lixte Biotechnology Holdings 10-Year ROIIC % Historical Data

The historical data trend for Lixte Biotechnology Holdings's 10-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings 10-Year ROIIC % Chart

Lixte Biotechnology Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

10-Year ROIIC %

Get a 7-Day Free Trial

-2,136.36

-242,600.00

-2,784.77

-10,614.29

Lixte Biotechnology Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
10-Year ROIIC %	Get a 7-Day Free Trial															-	-	-	-10,614.29	-

Competitive Comparison of Lixte Biotechnology Holdings's 10-Year ROIIC %

For the Biotechnology subindustry, Lixte Biotechnology Holdings's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lixte Biotechnology Holdings's 10-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's 10-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Lixte Biotechnology Holdings's 10-Year ROIIC % falls into.

Lixte Biotechnology Holdings 10-Year ROIIC % Calculation

Lixte Biotechnology Holdings's 10-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

10-Year ROIIC %	=	10-Year Incremental Net Operating Profit After Taxes (NOPAT)^**	/	10-Year Incremental Invested Capital^**
	=	( -5.09 (Dec. 2023) - -1.375 (Dec. 2013) )	/	( 0.157 (Dec. 2023) - 0.122 (Dec. 2013) )
	=	-3.715	/	0.035
	=	-10,614.29%^***

** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Lixte Biotechnology Holdings (NAS:LIXT) 10-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.

Lixte Biotechnology Holdings 10-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (NAS:LIXT) » Definitions » 10-Year ROIIC %

Comparable Companies

Traded in Other Exchanges

N/A

Address

680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101

Website

https://www.lixte.com

Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.

Executives

Rene Bernards	director	KONINGSVAREN 37, ABCOUDE P7 1391AD
Van Der Baan Bastiaan Jeroen	director	HOGEWEG 4-H, AMSTERDAM P7 1098CB
Eric Forman	10 percent owner	117 E. 29TH ST., APT. 5A, NEW YORK NY 10016
Regina Brown	director	248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733
Glenn Krinsky	10 percent owner	C/O SRKP 1, INC., 1900 AVENUE OF THE STARS, SUITE 310, LOS ANGELES CA 90067
Yun Yen	director	1301 OAKLAWN ROAD, ARCADIA CA 91006
Robert Greenberg	10 percent owner	SKECHERS USA INC, 228 MANHATTAN BEACH BLVD, MANHATTAN BEACH CA 90266
Gil Schwartzberg	10 percent owner	269 S. BEVERLY DR., #1315, BEVERLY HILLS CA 90212
Philip F Palmedo	director	1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067
John S Kovach	director, 10 percent owner, officer: Pres., CFO & Secty	1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067
Stephen J. Forman	director	248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733
Hung Tak Ho	10 percent owner	MAYFAIR BY THE SEA II, TOWER T8, 1/F, UNIT A, 21 FO CHUN ROAD, PAK SHEK KOK, TAIPO K3 00000
Robert N Weingarten	officer: Vice President and CFO	5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367
James Miser	officer: Chief Medical Officer	680 E COLORADO BLVD., SUITE 180, PASADENA CA 91101
Jane Merrill Riggs	10 percent owner	4852 SAINT ANDRES AVENUE, LA VERNE CA 91750